Xilio Therapeutics Inc Pipeline Progress and SITC Update Transcript
Good morning, and welcome to the Xilio Therapeutics conference call. (Operator Instructions) Please be advised that this call is being recorded. At this time, I would like to turn the call over to your host, Stacey Davis at Xilio Therapeutics.
Good morning, everyone. I'm Stacey Davis, Chief Business Officer of Xilio Therapeutics, and I'd like to welcome you all to our pipeline progress and SITC update call. Today, we'll be reviewing progress across our clinical pipeline, including the initial Phase 1/2 clinical data presented at SITC last week for XTX202, our tumor-activated engineered, beta-gamma IL-2.
On Friday, we issued a press release announcing the XTX202 data reported at SITC. You can access the press release and slides from today's presentation by going to the Investors and Media section of our corporate website.
Before we get started, I'd like to remind everyone that the statements we make on this conference call will include forward-looking statements. Actual events or
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |